National Health Act 1953 - Amendment determination under sections 85, 85A and 88 - pharmaceutical benefits (No. PB 2 of 2009)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), which ensures Australians have reliable, timely, and affordable access to a broad range of medicines. The Act enables the Commonwealth to provide pharmaceutical benefits in accordance with Part VII. The 2009 legislative instrument, numbered PB 2 of 2009, amends previous determinations made under sections 85, 85A, and 88 of the Act to reflect the recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC). This instrument, which commenced on 1 February 2009, updates the list of pharmaceutical items eligible for PBS subsidies, modifies the forms and brands of certain medications, and adjusts the parameters for prescription writing. The amendments aim to enhance the efficiency and effectiveness of the PBS by ensuring that the scheme remains aligned with the latest clinical evidence and cost-effectiveness considerations.

Scope and Application

The Pharmaceutical Benefits Scheme (PBS) under Part VII of the National Health Act 1953 is designed to provide Australians with reliable, timely, and affordable access to a broad range of medicines. This legislative instrument, effective from 1 February 2009, amends previous determinations made in 2008 to reflect recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). It specifically addresses the listing of new drugs and brands, modifications to existing drug forms, and updates to prescription regulations. The amendments pertain to the forms and brands of certain drugs, including the addition of new brands like Alendronic Acid, Carvedilol, and Metformin, as well as the deletion of others such as Atenolol and Trandolapril. Additionally, the instrument modifies the forms of certain drugs and updates the brand names and descriptions, reflecting changes recommended by the PBAC. This legislation applies nationwide across Australia, impacting pharmaceutical entities, healthcare providers, and consumers by governing the types of drugs covered by the PBS, the permissible forms and brands, and the conditions under which these drugs can be prescribed.

Key Provisions

The main operative sections of the legislation, F2009L00043, focus on the determinations under sections 85, 85A, and 88 of the National Health Act 1953. Subsection 85(1) mandates the provision of pharmaceutical benefits by the Commonwealth in accordance with Part VII of the Act, which is the foundation of the Pharmaceutical Benefits Scheme (PBS). Subsection 85(2) allows the Minister to declare by legislative instrument which drugs and medicinal preparations are to be included as listed drugs under the scheme. Furthermore, subsection 85(3) authorises the Minister to determine the form or forms of a listed drug, while subsection 85(5) allows the Minister to specify the manner of administration for such forms. Subsection 85(6) enables the Minister to determine the brand of a pharmaceutical item. Additionally, subsection 85A(2) empowers the Minister to set various parameters concerning the writing of prescriptions, such as the maximum quantity, repetition frequency, and manner of administration. Finally, subsection 88(1A) allows the Minister to determine the pharmaceutical benefits for which a dental practitioner can write a prescription. The obligations imposed by the Act on the parties it governs are primarily centred around compliance with the determinations made by the Minister. Pharmaceutical companies and medical practitioners must adhere to the specifications set for listed drugs, their forms, brands, and prescription writing. For example, pharmaceutical companies must ensure that their products comply with the declared forms and brands as stipulated by the Minister. Medical practitioners, on the other hand, must follow the prescription parameters, such as the maximum quantity and repetition frequency, to ensure they are within the allowable limits set forth by the Act. Breaches of the provisions under this legislation can result in various civil or criminal consequences. While the specific penalties are not detailed in the explanatory statement, it is generally understood that non-compliance with pharmaceutical regulations can lead to substantial fines, product recalls, or even criminal charges in severe cases. For instance, if a pharmaceutical company fails to comply with the declared forms or brands for their products, they may face penalties that could include fines or legal action. Similarly, medical practitioners who issue prescriptions that do not adhere to the stipulated parameters could face disciplinary actions from their professional boards, fines, or other legal repercussions. The exact penalties would depend on the nature and severity of the breach, as well as any applicable laws or regulations.